{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:52:07Z","timestamp":1778356327288,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bone.2024.117371","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:36:36Z","timestamp":1734050196000},"page":"117371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial"],"prefix":"10.1016","volume":"192","author":[{"given":"Yoon-Sok","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Plebanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Mydlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Sapula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rowi\u0144ska-Osuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrone","family":"Urboniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mordaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohui","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hee","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisuk","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2024.117371_bb0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.bone.2024.117371_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2021.10.010","article-title":"Disparities in osteoporosis care among postmenopausal women in the United States","volume":"156","author":"Ruiz-Esteves","year":"2022","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2024.117371_bb0015","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"Eastell","year":"2016","journal-title":"Postmenopausal osteoporosis. Nat Rev Dis Primers."},{"issue":"9","key":"10.1016\/j.bone.2024.117371_bb0020","volume":"14","author":"Bhatnagar","year":"2022","journal-title":"Postmenopausal Osteoporosis: A Literature Review. Cureus."},{"issue":"3","key":"10.1016\/j.bone.2024.117371_bb0025","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2024.117371_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.bone.2024.117371_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001637","article-title":"Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects","volume":"7","author":"Smolen","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.bone.2024.117371_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.572569","article-title":"Pharmacoeconomic evaluation of Cancer Biosimilars worldwide: a systematic review","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bone.2024.117371_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The future of Biosimilars: maximizing benefits across immune-mediated inflammatory diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bone.2024.117371_bb0050","unstructured":"US Food and Drug Administration: Biological Product Definitions. https:\/\/www.fda.gov\/files\/drugs\/published\/Biological-Product-Definitions.pdf Accessed 27 August 2024."},{"key":"10.1016\/j.bone.2024.117371_bb0055","unstructured":"US Food and Drug Administration: Biosimilar Product Information. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information Accessed 27 August 2024."},{"key":"10.1016\/j.bone.2024.117371_bb0060","unstructured":"European Medicines Agency: Biosimilars in the EU - Information guide for healthcare professionals. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (2019). Accessed 27 August 2024."},{"key":"10.1016\/j.bone.2024.117371_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bone.2024.117371_bb0070","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae611","article-title":"Proposed Denosumab biosimilar SB16 vs reference Denosumab in postmenopausal osteoporosis: phase 3 results up to month 12","author":"Langdahl","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2024.117371_bb0075","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","article-title":"Are we ready to close the discussion on the interchangeability of biosimilars?","volume":"24","author":"Ebbers","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.bone.2024.117371_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and Biosimilars: a systematic review","volume":"108","author":"Barbier","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bone.2024.117371_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292231","article-title":"Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis","volume":"18","author":"Herndon","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bone.2024.117371_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30485-X","article-title":"Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the southern network on adverse reactions","volume":"21","author":"Bennett","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bone.2024.117371_bb0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of originator biologics and Biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.bone.2024.117371_bb0100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40273-014-0163-9","article-title":"Barriers to the uptake of biosimilars and possible solutions: a Belgian case study","volume":"32","author":"Dylst","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.bone.2024.117371_bb0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2024.117371_bb0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2024.117371_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis","author":"Reginster","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2024.117371_bb0120","unstructured":"European Medicines Agency: Prolia SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf (2024). Accessed September 24 2024."},{"key":"10.1016\/j.bone.2024.117371_bb0125","unstructured":"US Food and Drug Administration: Prolia Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125320s213lbl.pdf (2023). Accessed September 24 2024."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224003600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224003600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T03:08:32Z","timestamp":1737774512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328224003600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S8756328224003600"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2024.117371","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2024.117371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117371"}}